Faricimab

Definition

A humanized bispecific antibody targeting both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), that is used for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema. Upon intravitreal administration, faricimab targets and binds to both VEGF-A and Ang-2, and prevents VEGF-A- and Ang-2-mediated signaling. The inhibition of VEGF-A-mediated signaling decreases endothelial cell proliferation, neovascularization and vascular permeability. The inhibition of Ang-2-mediated signaling improves vascular stability and desensitizes blood vessels to the effects of VEGF-A. VEGF and Ang-2, upregulated in some eye diseases, play important roles in pathological neovascularization and increased vascular permeability and inflammation, which may lead to vision loss.

Also known as FARICIMAB, Faricimab-svoa, RG 7716, RG-7716, RG7716, RO 6867461, RO-6867461, RO6867461, Vabysmo — per NCIT

Also identified as

• ATC S01LA09 per RXNORM
• NCIT NCIT:C174885 per NCIT
• SCTID 278201000202106 per RXNORM
• UNII QC4F7FKK7I per RXNORM

Indications

Organ Effects

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.